瑞财经 刘治颖7月28日,和铂医药-B(02142)公告,预期截至2025年6月30日止六个月的溢利介乎约6800万美元(相当于约5.32亿港元)至约7400万美元(相当于约5.79亿港元)。而2024年上半年,和铂医药实现整体收入约2370.1万美元,归母净利润约142.4万美元。和铂医药表示,预期溢利增加主要归因于与全球制药公司持续保持战略合作伙伴关系,例如与阿斯利康开展全球战略合作;集团已...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.